Navidea Biopharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy NAVB

*Your capital is at risk

$0.0001

+0 (+0%)

At Close: Dec 30, 2025

Navidea Biopharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at 0. In total, the insiders bought 51.36M and sold 42.22K NAVB shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	0
● Buy	51.36M shares
● Sell	42.22K shares
88% Buy Activity Negligible or No Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Nov 27, 2023 Buy	Series J Convertible Preffered Stock J-Other	Scott John K Jr.	Director	64 289 Value: $7K
Nov 27, 2023 Sell	Series G Redeemable Preferred Stock J-Other	Scott John K Jr.	Director	2 270 Value: $2
Nov 27, 2023 Sell	Series I Convertible Preferred Stock J-Other	Scott John K Jr.	Director	2 400 Value: $384
Nov 27, 2023 Sell	Series I Convertible Preferred Stock J-Other	Scott John K Jr.	Director	2 400 Value: $384
Nov 27, 2023 Sell	Series G Redeemable Preferred Stock J-Other	Scott John K Jr.	Director	2 270 Value: $2
Nov 27, 2023 Buy	Series J Convertible Preffered Stock J-Other	Scott John K Jr.	Director	64 289 Value: $7K
Nov 16, 2023 Buy	Common Stock A-Award	Moss Dana J Director	Director	416 667 Value: $0
Nov 16, 2023 Buy	Common Stock A-Award	Moss Dana J Director	Director	200 000 Value: $0
Nov 16, 2023 Buy	Common Stock A-Award	Stefanelli Jill Director	Director	416 667 Value: $0
Nov 16, 2023 Buy	Common Stock A-Award	Stefanelli Jill Director	Director	275 000 Value: $0
Nov 16, 2023 Buy	Common Stock A-Award	Stefanelli Jill Director	Director	275 000 Value: $0
Nov 16, 2023 Buy	Common Stock A-Award	Stefanelli Jill Director	Director	416 667 Value: $0
Nov 16, 2023 Buy	Common Stock A-Award	Moss Dana J Director	Director	200 000 Value: $0
Nov 16, 2023 Buy	Common Stock A-Award	Moss Dana J Director	Director	416 667 Value: $0
Jul 28, 2023 Buy	Common Stock J-Other	Dais Craig Insider	Other	0 Value: $0
Jul 28, 2023 Buy	Common Stock J-Other	Dais Craig Insider	Other	0 Value: $0
Jul 11, 2023 Buy	Common Stock A-Award	Moss Dana J Director	Director	250 000 Value: $0
Jul 11, 2023 Buy	Common Stock J-Other	Moss Dana J Insider	Other	0 Value: $0
Jul 11, 2023 Buy	Common Stock J-Other	Moss Dana J Insider	Other	0 Value: $0
Jul 11, 2023 Buy	Common Stock A-Award	Moss Dana J Director	Director	250 000 Value: $0
Jun 29, 2023 Buy	Common Stock A-Award	Scott John K Jr.	Director	12 200 000 Value: $1.07M
Jun 29, 2023 Buy	Common Stock A-Award	Scott John K Jr.	Director	12 200 000 Value: $1.07M
Jun 08, 2023 Buy	Common Stock A-Award	Stefanelli Jill Director	Director	250 000 Value: $0
Jun 08, 2023 Buy	Common Stock A-Award	Stefanelli Jill Director	Director	250 000 Value: $0
Jun 05, 2023 Buy	Common Stock A-Award	Scott John K Jr.	Director	11 508 672 Value: $11.5K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT NAVIDEA BIOPHARMACEUTICALS INC

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission c...

Read Full Profile Here